Watch the videos in this series and learn about icosapent ethyl in relation to CV risk and its potential mechanisms of action!

This lecture by prof. Chris Packard, PhD is part of an educational series entitled "CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl".

This lecture by prof. Alberto Zambon, MD, PhD is part of an educational series entitled "CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl".

This lecture by prof. Wouter Jukema, MD, PhD is part of an educational series entitled "CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl".

Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.

Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.

Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in patients who are already being treated with statins.